Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Public ClinicalTrials.gov record NCT01395823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm. The investigators propose to conduct a double blind, randomized, placebo controlled clinical trial of ergocalciferol supplementation to confirm safety and determine effects on Erythropoietin (EPO) dosing, active D dosing, and mineral metabolic parameters in hemodialysis patients.
Study identification
- NCT ID
- NCT01395823
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Interventions
- ergocalciferol supplementation Dietary Supplement
- placebo Other
Dietary Supplement · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2011 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Jun 2015 (Actual)
- Last update posted
- Mar 14, 2016
2011 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| DCI - Redding | Redding | California | 96003 | — |
| DCI - Albany | Albany | Georgia | 31701 | — |
| DCI - Shreveport | Shreveport | Louisiana | 71103 | — |
| DCI - Boston | Boston | Massachusetts | 02111 | — |
| DCI- Columbia | Columbia | Missouri | 65201 | — |
| DCI - Kansas City | Kansas City | Missouri | 64131 | — |
| DCI- Omaha | Omaha | Nebraska | 68131 | — |
| DCI - New Brunswick | New Brunswick | New Jersey | 08903 | — |
| DCI - North Brunswick | North Brunswick | New Jersey | 08902 | — |
| DCI - Philadelphia | Philadelphia | Pennsylvania | 19129 | — |
| DCI - Knoxville | Knoxville | Tennessee | 37924 | — |
| DCI - Maryville | Maryville | Tennessee | 37804 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01395823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2016 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01395823 live on ClinicalTrials.gov.